Tehran University of Medical Sciences
tums.ac.irLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
229
Active
10
Phase 3
66
Total enrollment
65,376
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intranasal Ketorolac Tromethamine | — | — | — | — | — | 1 | |
| Intranasal ketamine | — | — | — | — | — | 1 | |
| N-Acetylcysteine 600mg/tab | — | — | — | — | — | 1 | |
| Drug-Eluting Embolic Bead | — | — | — | — | — | 1 | |
| Chemotherapy drug | — | — | — | — | — | 1 | |
| Mesenchymal Stem Cells Derived Exosomes | — | — | — | — | — | 1 |
Next readouts
- 2024-10
- 2025-03-08
- 2026-06-20
- 2027-10
Top conditions
- Pain8
- Type 2 Diabetes Mellitus8
- Hepatitis C5
- Obesity5
- Relapsing Remitting Multiple Sclerosis5
- Cardiovascular Disease4
- Behcet's Syndrome4
- Leukemia, Myeloid, Acute3
Frequently asked questions about Tehran University of Medical Sciences
- How many clinical trials does Tehran University of Medical Sciences have on ClinicalTrials.gov?
- Tehran University of Medical Sciences is listed as the lead sponsor on 229 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Tehran University of Medical Sciences's trials are in Phase 3?
- 66 of Tehran University of Medical Sciences's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Tehran University of Medical Sciences focus on?
- Tehran University of Medical Sciences's most-studied conditions on ClinicalTrials.gov are Pain, Type 2 Diabetes Mellitus, Hepatitis C, Obesity, Relapsing Remitting Multiple Sclerosis.
- When are Tehran University of Medical Sciences's next clinical trial readouts?
- Tehran University of Medical Sciences has 4 upcoming primary-completion readouts tracked here; the soonest is “Effects of Exosome Adminstration in Preventing Early Leakage in Rectal Cancer Patients Undergoing Low Anterior Resection”, expected around 2024-10.